Summary: A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.

Top Publications

  1. Amiri A, Noorbala A, Nejatisafa A, Ghoreishi A, Derakhshan M, Khodaie Ardakani M, et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Hum Psychopharmacol. 2008;23:79-86 pubmed
    It has been reported that selegiline, a Selective Monoamine Oxidase Inhibitor B (MAOI-B), at low doses would be helpful for treating negative symptoms in schizophrenia. Nevertheless, the results are contradictory so far...
  2. Siu E, Tyndale R. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J Pharmacol Exp Ther. 2008;324:992-9 pubmed
    b>Selegiline (l-deprenyl) is in clinical treatment trials as a potential smoking cessation drug. We investigated the affect of selegiline and its metabolites on nicotine metabolism...
  3. Parvizpour A, Charkhpour M, Habibi Asl B, Shakhsi M, Ghaderi M, Hassanzadeh K. Repeated central administration of selegiline attenuated morphine physical dependence in rat. Pharmacol Rep. 2013;65:593-9 pubmed
    ..The purpose of this study was to evaluate the effects of systemic and intracerebroventricular (icv) administration of selegiline (a selective inhibitor of monoamine oxidase B) on the morphine withdrawal syndrome in rats.
  4. Frampton J, Plosker G. Selegiline transdermal system in major depressive disorder: profile report. CNS Drugs. 2007;21:521-4 pubmed
  5. Fabbrini G, Abbruzzese G, Marconi S, Zappia M. Selegiline: a reappraisal of its role in Parkinson disease. Clin Neuropharmacol. 2012;35:134-40 pubmed publisher
    b>Selegiline at the doses used in Parkinson disease is a selective irreversible monoamine oxidase type B inhibitor, which potentiates dopaminergic function in the brain, and is used as monotherapy in early Parkinson disease or in ..
  6. Tazik S, Johnson S, Lu D, Johnson C, Youdim M, Stockmeier C, et al. Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotox Res. 2009;15:284-90 pubmed publisher
    ..In this study, we have compared the ability of rasagiline (Azilect) and its main metabolite, R-aminoindan with selegiline (Deprenyl) in prevention of dexamethasone-induced brain cell death employing human neuroblastoma SH-SY5Y cells ..
  7. Bodkin J, Amsterdam J. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159:1869-75 pubmed
    The authors investigated the efficacy and safety of transdermal selegiline in adult outpatients with major depressive disorder.
  8. Shimazu S, Minami A, Kusumoto H, Yoneda F. Antidepressant-like effects of selegiline in the forced swim test. Eur Neuropsychopharmacol. 2005;15:563-71 pubmed
    Although selegiline, a monoamine oxidase (MAO)-B inhibitor, is reported to exert antidepressant effects in depressant patients, evidence in rodents for effects of selegiline is quite limited...
  9. Ghorbanian M, Tiraihi T, Mesbah Namin S, Fathollahi Y. Selegiline is an efficient and potent inducer for bone marrow stromal cell differentiation into neuronal phenotype. Neurol Res. 2010;32:185-93 pubmed publisher
    ..Many of these chemicals were reported to be of mutagenic, teratogenic or carcinogenic properties. The purpose of this work was to evaluate the neuronal inductivity of selegiline to BMSCs.

More Information


  1. Mizuno Y, Kondo T, Kuno S, Nomoto M, Yanagisawa N. Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease. Clin Neuropharmacol. 2010;33:1-4 pubmed publisher
    To evaluate the clinical outcome of Parkinson disease (PD) patients treated with selegiline (with L-Dopa/decarboxylase inhibitor) in the early stage of the disease in comparison with that of late-stage use of selegiline.
  2. Waters C, Sethi K, Hauser R, Molho E, Bertoni J. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19:426-32 pubmed
    Zydis selegiline dissolves on contact with saliva and undergoes pregastric absorption. This minimizes first-pass metabolism and provides high plasma concentrations of selegiline...
  3. Bert B, Harms S, Langen B, Fink H. Clomipramine and selegiline: do they influence impulse control?. J Vet Pharmacol Ther. 2006;29:41-7 pubmed
    ..The reduction of these undesirable actions is the focus of behaviour therapy. Clomipramine and selegiline have been approved for the treatment of separation anxiety in dogs, but there are anecdotal reports that they ..
  4. Bar Am O, Amit T, Youdim M. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett. 2004;355:169-72 pubmed
    The anti-Parkinson selective irreversible monoamine oxidase B inhibitor drugs, rasagiline and selegiline, have been shown to possess neuroprotective activities in cell culture and in vivo models...
  5. Chetsawang B, Kooncumchoo P, Govitrapong P, Ebadi M. 1-Methyl-4-phenyl-pyridinium ion-induced oxidative stress, c-Jun phosphorylation and DNA fragmentation factor-45 cleavage in SK-N-SH cells are averted by selegiline. Neurochem Int. 2008;53:283-8 pubmed publisher
    ..In addition, there are several studies demonstrating that selegiline protects neural cell degeneration...
  6. Biberman R, Neumann R, Katzir I, Gerber Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction. 2003;98:1403-7 pubmed
    To compare the effect of oral selegiline plus nicotine patch with placebo plus nicotine patch on smoking cessation rates.
  7. Salonen J, Nyman L, Boobis A, Edwards R, Watts P, Lake B, et al. Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003;31:1093-102 pubmed
    b>Selegiline was used as a model compound in a project aimed at comparing, evaluating, and integrating different in vitro approaches for the prediction of cytochrome p450 (p450)-catalyzed hepatic drug metabolism in humans (EUROCYP)...
  8. Carageorgiou H, Zarros A, Tsakiris S. Selegiline long-term effects on brain acetylcholinesterase, (Na+,K+)-ATPase activities, antioxidant status and learning performance of aged rats. Pharmacol Res. 2003;48:245-51 pubmed
    The aim of this study was to investigate the effects of selegiline ((-)deprenyl), an irreversible inhibitor of monoaminoxidase-B (MAO-B): (a) on brain acetylcholinesterase (AChE), (Na(+),K(+))-ATPase and Mg(2+)-ATPase activities; (b) ..
  9. Elkashef A, Fudala P, Gorgon L, Li S, Kahn R, Chiang N, et al. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug Alcohol Depend. 2006;85:191-7 pubmed
    Cocaine dependence is a major public health problem for which there is no FDA-approved pharmacological treatment. Selegiline is an irreversible selective inhibitor of monoamine oxidase type B (MAO-B) which may affect cocaine addiction ..
  10. Ebadi M, Brown Borg H, Ren J, Sharma S, Shavali S, El Refaey H, et al. Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr Drug Targets. 2006;7:1513-29 pubmed
    b>Selegiline inhibits the activity of monoamine oxidase B, enhances the release of dopamine, blocks the uptake of dopamine, acts as a calmodulin antagonist, and enhances the level of cyclic AMP, which in turn protects dopaminergic neurons...
  11. Newton T, De La Garza R, Fong T, Chiang N, Holmes T, Bloch D, et al. A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline. Pharmacol Biochem Behav. 2005;82:704-11 pubmed
    b>Selegiline (L-deprenyl) is a selective irreversible monoamine oxidase B inhibitor shown to be effective in the treatment of Parkinson's and Alzheimer's diseases...
  12. Mohammadi M, Ghanizadeh A, Alaghband Rad J, Tehranidoost M, Mesgarpour B, Soori H. Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial. J Child Adolesc Psychopharmacol. 2004;14:418-25 pubmed
    The aim of this study was to examine the selegiline treatment compared to methylphenidate (MPH) in children and adolescents with attention deficit hyperactivity disorder (ADHD).
  13. Jenei V, Zor K, Magyar K, Jakus J. Increased cell-cell adhesion, a novel effect of R-(-)-deprenyl. J Neural Transm (Vienna). 2005;112:1433-45 pubmed
    ..The effect of R-(-)-deprenyl was not reversible during a 24-hour recovery period. In summary, we described a new, MAO-B independent effect of R-(-)-deprenyl on cell-cell adhesion which can contribute to its neuroprotective function...
  14. Marras C, McDermott M, Rochon P, Tanner C, Naglie G, Rudolph A, et al. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology. 2005;64:87-93 pubmed
    ..To investigate predictors of survival in Parkinson disease (PD)...
  15. Abassi Z, Binah O, Youdim M. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol. 2004;143:371-8 pubmed
    b>Selegiline is used for treating Parkinson's disease...
  16. Zhao Y, Wee H, Au W, Seah S, Luo N, Li S, et al. Selegiline use is associated with a slower progression in early Parkinson's disease as evaluated by Hoehn and Yahr Stage transition times. Parkinsonism Relat Disord. 2011;17:194-7 pubmed publisher
    This study was carried out to evaluate the association between selegiline use and Parkinson's disease (PD) progression in a clinical sample by evaluating modified Hoehn and Yahr Stage (H&Y) stage transition times...
  17. Carter S, Scholl M, Almkvist O, Wall A, Engler H, Langstrom B, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med. 2012;53:37-46 pubmed publisher
    ..Along with (11)C-DED PET, (11)C-Pittsburgh compound B ((11)C-PIB; fibrillar A? deposition), (18)F-FDG (glucose metabolism), T1 MRI, cerebrospinal fluid, and neuropsychologic data were acquired from the patients...
  18. Fang J, Hung C, Chi C, Chen C. Transdermal permeation of selegiline from hydrogel-membrane drug delivery systems. Int J Pharm. 2009;380:33-9 pubmed publisher
    In the present work, we attempted to design a transdermal system for delivering selegiline using a hydrogel-based drug reservoir and a rate-controlling membrane (Solupor polyethylene membranes)...
  19. Lyons K, Friedman J, Hermanowicz N, Isaacson S, Hauser R, Hersh B, et al. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin Neuropharmacol. 2010;33:5-10 pubmed publisher
    To determine whether adding orally disintegrating selegiline (ODS) while decreasing dopamine agonist (DA) dosages would reduce DA-related adverse effects (AEs) of excessive daytime sleepiness (EDS), pedal edema, hallucinations, and ..
  20. Dodam J, Cohn L, Durham H, Szladovits B. Cardiopulmonary effects of medetomidine, oxymorphone, or butorphanol in selegiline-treated dogs. Vet Anaesth Analg. 2004;31:129-37 pubmed
    To determine if chronic selegiline HCl administration affects the cardiopulmonary response to medetomidine, oxymorphone, or butorphanol in dogs.
  21. Riederer P, Lachenmayer L. Selegiline's neuroprotective capacity revisited. J Neural Transm (Vienna). 2003;110:1273-8 pubmed
  22. Patkar A, Pae C, Zarzar M. Transdermal selegiline. Drugs Today (Barc). 2007;43:361-77 pubmed
    ..Efforts to address these safety issues led to the development of a transdermal formulation of selegiline, called selegiline transdermal system (STS). STS has been approved by the U.S...
  23. Houtsmuller E, Thornton J, Stitzer M. Effects of selegiline (L-deprenyl) during smoking and short-term abstinence. Psychopharmacology (Berl). 2002;163:213-20 pubmed
    ..Medications that modulate dopamine levels may have beneficial effects on both withdrawal symptom levels and on response to smoking lapses during abstinence...
  24. Naoi M, Maruyama W, Inaba Hasegawa K. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms. Expert Rev Neurother. 2013;13:671-84 pubmed publisher
    ..In cellular and animal models, selegiline [(-)deprenyl] and rasagiline, inhibitors of type B monoamine oxidase (MAO)-B, protect neuronal cells from ..
  25. Azzaro A, Ziemniak J, Kemper E, Campbell B, VanDenBerg C. Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications. J Clin Pharmacol. 2007;47:146-58 pubmed
    b>Selegiline transdermal system (STS) is a recently approved monoamine oxidase inhibitor antidepressant...
  26. Evans S, Yeh T, Sacktor N, Clifford D, Simpson D, Miller E, et al. Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials. 2007;8:437-46 pubmed
    To assess the long-term safety (primary aim) and efficacy (secondary aim) of the MAO-B inhibitor Selegiline Transdermal System (STS) for the treatment of HIV-associated cognitive impairment.
  27. Ebadi M, Sharma S, Shavali S, Sangchot P, Brekke L. The multiple actions of selegiline. Proc West Pharmacol Soc. 2002;45:39-41 pubmed
  28. Azzaro A, Ziemniak J, Kemper E, Campbell B, VanDenBerg C. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007;47:1256-67 pubmed
    The selegiline transdermal system is a monoamine oxidase inhibitor that was recently approved by the US Food and Drug Administration for the treatment of major depressive disorder...
  29. Tzanavaras P, Themelis D, Zotou A, Stratis J, Karlberg B. Optimization and validation of a dissolution test for selegiline hydrochloride tablets by a novel rapid HPLC assay using a monolithic stationary phase. J Pharm Biomed Anal. 2008;46:670-5 pubmed publisher
    The present study reports the optimization and validation of a dissolution test for selegiline.HCl tablets using a new high-performance liquid chromatographic (HPLC) method...
  30. Azzaro A, VanDenBerg C, Blob L, Kemper E, Sharoky M, Oren D, et al. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. J Clin Pharmacol. 2006;46:933-44 pubmed
    The oral tyramine pressor test was administered to healthy males during treatment with a selegiline transdermal system (STS; 6 mg/24 h)...
  31. Takahata K, Minami A, Kusumoto H, Shimazu S, Yoneda F. Effects of selegiline alone or with donepezil on memory impairment in rats. Eur J Pharmacol. 2005;518:140-4 pubmed
    b>Selegiline, a monoamine oxidase-B inhibitor, is reported to improve memory and learning in dementia of Alzheimer's type. However, only a few studies have reported its use in animal models...
  32. Tsunekawa H, Noda Y, Mouri A, Yoneda F, Nabeshima T. Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35). Behav Brain Res. 2008;190:224-32 pubmed publisher
    b>Selegiline, an irreversible inhibitor of monoamine oxidase B used in the treatment of Parkinson's disease, has been demonstrated to have a potential cognition-improving effect in patients with Alzheimer's disease (AD) undergoing treatment ..
  33. Magyar K. The pharmacology of selegiline. Int Rev Neurobiol. 2011;100:65-84 pubmed publisher
    b>Selegiline, the R-optical enantiomer of deprenyl (phenyl-isopropyl-methyl-propargylamine), was almost exclusively used MAO-B inhibitor during the past decades to treat Parkinson's disease...
  34. Jang S, Jung S, Pae C, Kimberly B, Craig Nelson J, Patkar A. Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS). J Affect Disord. 2013;151:854-9 pubmed publisher
    We investigated patient and disease characteristics predictive of relapse of MDD during a 52-week placebo controlled trial of selegiline transdermal system (STS) to identify patient characteristics relevant for STS treatment.
  35. Mawhinney M, Cole D, Azzaro A. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol. 2003;55:27-34 pubmed
    b>Selegiline has been formulated in an acrylic polymer adhesive mixture to be employed as a constant release topical patch for daily transdermal administration...
  36. West B, Shughrue P, Vanko A, Ransom R, Kinney G. Amphetamine-induced locomotor activity is reduced in mice following MPTP treatment but not following selegiline/MPTP treatment. Pharmacol Biochem Behav. 2006;84:158-61 pubmed
    ..Further, the potential for use of this endpoint to evaluate putative therapeutics is exemplified by the amelioration of these effects following pre-treatment with the MAO-B inhibitor selegiline.
  37. Sharma S, Carlson E, Ebadi M. Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons. J Neurocytol. 2003;32:329-43 pubmed
    ..4-phenyl, Pyridinium ion (MPP(+)) in SK-N-SH neurons and have evaluated the neuroprotective potential of Selegiline with a primary objective to explore its mechanism(s) of neuroprotection...
  38. Simon L, Szilagyi G, Bori Z, Telek G, Magyar K, Nagy Z. Low dose (-)deprenyl is cytoprotective: it maintains mitochondrial membrane potential and eliminates oxygen radicals. Life Sci. 2005;78:225-31 pubmed
  39. Anttila M, Sotaniemi E, Pelkonen O, Rautio A. Marked effect of liver and kidney function on the pharmacokinetics of selegiline. Clin Pharmacol Ther. 2005;77:54-62 pubmed
    The pharmacokinetics of selegiline was investigated in an open study with 4 parallel groups of 10 subjects in each...
  40. Qin F, Shite J, Mao W, Liang C. Selegiline attenuates cardiac oxidative stress and apoptosis in heart failure: association with improvement of cardiac function. Eur J Pharmacol. 2003;461:149-58 pubmed
    We have shown recently that selegiline exerts a cardiac neuroprotective effect in chronic heart failure...
  41. Bhattacharya K, Nouri S, Olanow C, Yahr M, Kaufmann H. Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension. Parkinsonism Relat Disord. 2003;9:221-4 pubmed
    Less than a consensus exists as to whether chronic treatment with selegiline in combination with levodopa/carbidopa in patients with Parkinson's disease, is associated with more pronounced orthostatic hypotension than treatment with ..
  42. Wecker L, James S, Copeland N, Pacheco M. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry. 2003;54:1099-104 pubmed
    ..These studies determined whether the transdermal administration of selegiline has differential effects on MAOs in brain versus the gastrointestinal system.
  43. Kwon Y, Ann H, Nabeshima T, Shin E, Kim W, Jhoo J, et al. Selegiline potentiates the effects of EGb 761 in response to ischemic brain injury. Neurochem Int. 2004;45:157-70 pubmed
    We evaluated whether combined treatment with selegiline, a selective MAO-B inhibitor, and EGb 761, a standard extract of Ginkgo biloba, has synergistic effects against ischemic reperfusion injury (IRI) in gerbils...
  44. Robinson D, Gilmor M, Yang Y, Moonsammy G, Azzaro A, Oren D, et al. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials. Psychopharmacol Bull. 2007;40:15-28 pubmed
    b>Selegiline transdermal system (STS) is efficacious for the treatment of major depressive disorder (MDD)...
  45. Feiger A, Rickels K, Rynn M, Zimbroff D, Robinson D. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry. 2006;67:1354-61 pubmed
    This study investigated the efficacy, safety, and tolerability of the selegiline transdermal system (STS) administered in a dose range of 6 mg/24 hours to 12 mg/24 hours for treating major depressive disorder (MDD).
  46. Amsterdam J, Bodkin J. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol. 2006;26:579-86 pubmed
    The selegiline transdermal system (STS) is a monoamine oxidase inhibitor (MAOI) with unique pharmacokinetic and pharmacodynamic properties that was developed to overcome limitations of orally administered MAOIs, particularly dietary ..
  47. Azzaro A, VanDenBerg C, Ziemniak J, Kemper E, Blob L, Campbell B. Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers. J Clin Pharmacol. 2007;47:978-90 pubmed
    b>Selegiline transdermal system is a recently approved monoamine oxidase inhibitor antidepressant...
  48. Newburn G, Newburn D. Selegiline in the management of apathy following traumatic brain injury. Brain Inj. 2005;19:149-54 pubmed
    To provide a brief review of apathy following traumatic brain injury (TBI) and describe the use of selegiline in a group of patients with this symptom.
  49. Hara M, Thomas B, Cascio M, Bae B, Hester L, Dawson V, et al. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci U S A. 2006;103:3887-9 pubmed
    ..In mice treated with the dopamine neuronal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), low doses of deprenyl prevent binding of GAPDH and Siah1 in the dopamine-enriched corpus striatum...
  50. Clarke A, Brewer F, Johnson E, Mallard N, Hartig F, Taylor S, et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm (Vienna). 2003;110:1241-55 pubmed
    ..studies were conducted in healthy volunteers to compare the pharmacokinetic and pharmacodynamic profiles of selegiline hydrochloride in a new formulation designed for buccal absorption "Zydis Selegiline" (1...
  51. Lohle M, Storch A. Orally disintegrating selegiline for the treatment of Parkinson's disease. Expert Opin Pharmacother. 2008;9:2881-91 pubmed
    The selective monoamine oxidase type B inhibitor selegiline is commonly administered as medical treatment to patients suffering from Parkinson's disease...
  52. Akhondzadeh S, Tavakolian R, Davari Ashtiani R, Arabgol F, Amini H. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:841-5 pubmed
    ..b>Selegiline is a type B monoamine oxidase inhibitor (MAOI) that is metabolized to amphetamine and methamphetamine stimulant ..
  53. Sridar C, Kenaan C, Hollenberg P. Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts. Drug Metab Dispos. 2012;40:2256-66 pubmed publisher
    b>Selegiline, the R-enantiomer of deprenyl, is used in the treatment of Parkinson's disease. Bupropion, an antidepressant, often used to treat patients in conjunction with selegiline, is metabolized primarily by CYP2B6...